Navigation Links
First targeted nanomedicine to enter human clinical studies
Date:4/4/2012

BOSTON, MAA team of scientists, engineers and physicians from Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.

BIND-014 is the first targeted and programmed nanomedicine to enter human clinical studies. The study will be electronically published in Science Translational Medicine on April 4, 2012.

In the study, the researchers demonstrate BIND-014's ability to effectively target a receptor expressed in tumors to achieve high tumor drug concentrations, as well as show remarkable efficacy, safety and pharmacological properties compared to the parent chemotherapeutic drug, docetaxel (Taxotere).

"BIND-014 demonstrates for the first time that it is possible to generate medicines with both targeted and programmable properties that can concentrate the therapeutic effect directly at the site of disease, potentially revolutionizing how complex diseases such as cancer are treated," said Omid Farokhzad, MD, a physician-scientist in the BWH Department of Anesthesiology, associate professor at HMS, and study co- senior author.

"Previous attempts to develop targeted nanoparticles have not successfully translated into human clinical studies because of the inherent difficulty of designing and scaling up a particle capable of targeting, long-circulation via immune-response evasion, and controlled drug release," said Robert Langer, ScD, David H. Koch Institute Professor, MIT and study co-senior author.

According to the researchers, the drug is the first of its kind to reach clinical evaluation and demonstrates a differentially high drug concentration in tumors by targeting drug encapsulated nanoparticles directly to the site of tumors. This leads to substantially better efficacy and safety.

In the study, the researchers produced data that include pharmacokinetic characteristics consistent with prolonged circulation and controlled drug release with plasma concentrations remaining up to at least 100-fold higher than conventional docetaxel for over 24 hours, as well as up to a 10-fold increase in intratumoral drug concentrations with prolonged and enhanced tumor growth suppression in multiple tumor models compared with conventional docetaxel.

Moreover, initial clinical data in a heavily pretreated patient population with 17 patients with advanced or metastatic solid tumor cancers indicated that BIND-014 displays pharmacological characteristics consistent with preclinical findings of differentiated pharmacokinetics and accumulation at tumor sites with clinical effects seen at doses as low as 20 percent of the normally prescribed docetaxel dose and in cancers in which docetaxel has minimal activity (e.g., cervical cancer).

"The development of BIND-014 demonstrates that drug properties such as solubility, metabolism, plasma binding, biodistribution and target tissue accumulation will no longer be constrained to the same extent by the drug chemical composition. It will also become the function of the physicochemical properties of nanoparticles. This will allow for an unprecedented ability to make better medicines for our patients as demonstrated by our emerging clinical data." said Farokhzad.

The researchers note that while the science and technology of BIND-014 builds upon docetaxel's mechanism of action, the emerging evidence is that BIND-014 significantly changes the biological effects of docetaxel by virtue of fundamental changes in pharmacology including major increases in tumor concentration.

To date, the researchers note that BIND-014 has been administered at doses of up to 75 mg/m2 and dose escalation is ongoing. It has been well-tolerated with no new toxicities observed.

"It has been a privilege to be a part of the team that developed this technology at its conception through its clinical translation. The emerging BIND-014 clinical data showing signals of efficacy even at relatively low doses validates the potential for the revolutionary impact of nanomedicines and is a paradigm shift for the treatment of cancer." said Philip W. Kantoff, MD, Chief Clinical Research Officer at DFCI, Professor of Medicine at Harvard Medical School, and study co-author.

"It is wonderful to witness a world-class team of scientists, engineers, physicians, for-profit and non-project organizations converge to develop this potentially revolutionary technology for treatment of cancers. The effectiveness of this team has been remarkable and serves as model for translational research" said Edward J. Benz, Jr. MD, President of DFCI, Richard and Susan Smith Professor of Medicine at Harvard Medical School.

The research and development of the first targeted programmable nanomedicine to show anti-tumor effects in humans represents the culmination of more than a decade of investigation initially carried out in academic labs at BWH and MIT, and supported by funding from the National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, The David H. Koch Institute for Integrative Cancer Research at MIT, the Prostate Cancer Foundation, philanthropic gift from David H. Koch, and the Dana-Farber Harvard Cancer Center Prostate Cancer SPORE; and subsequently carried out in the laboratories of BIND Biosciences leading to the development of BIND-014, and supported by funding from the National Cancer Institute, National Institute of Standards and Technology and BIND Biosciences.

BIND Biosciences was launched in 2007 based on technologies that were licensed from BWH and MIT and developed, respectively, in the laboratories of Drs. Omid Farokhzad and Robert Langer, co-founders of BIND Biosciences, the biopharmaceutical company responsible for developing BIND-014.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. First Bedside Gene Test Shows Promise
2. Complications in patients undergoing PCI tend to occur within first 30 days
3. $4.2 million grant helps plan, launch first Alzheimers prevention trials
4. First national guideline for sudden hearing loss published
5. Researchers develop first theranostic treatment for acute lymphoblastic leukemia (ALL)
6. First study of its kind finds no increased risk of heart disease for kidney donors
7. UC San Diego among first in nation to treat brain cancer with novel viral vector
8. First breakdown of public health data for Cleveland neighborhoods
9. Rapid Flu Tests a Good First Step: Study
10. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
11. Mount Sinai first to use visually guided catheter ablation system to treat AFib patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2020)... ... 11, 2020 , ... Help.org , a trusted online resource for individuals ... in Greenville, for 2020. The informational guide recognizes the top 8 rehab facilities ... recent studies , drug overdose is the leading cause of death among people ...
(Date:8/11/2020)... ... ... has seen a drastic change in how things are done on a daily basis due ... mask in public. Now, most states have made it compulsory as the need for authentic ... professionals in the U.S.A realized the shortage of PPE was inevitable. Dr. Rouhanian was no ...
(Date:8/9/2020)... ... , ... Dr. Angela Abraham has been appointed as the first-ever Diversity and ... leading the drive to foster a more equitable and bias-free NECO community. , In ... initiative led by Black Eyecare Perspective and dedicated to increasing Black presence in vision ...
(Date:8/7/2020)... ... 07, 2020 , ... Alexandria Dental Health & Smile Studio ... Mazhari, this well-respected practice offers advanced smile solutions to meet all of their ... exclusive group of dental practices with a large number of five-star ratings and ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... (SEL) program, has been named to the inaugural list of Best Digital Tools ... , This recognition honors electronic resources that provide enhanced learning and curriculum development ...
Breaking Medicine News(10 mins):
(Date:8/12/2020)... ... 12, 2020 , ... Planet DDS is pleased to announce ... has acquitted 100% of Apteryx Imaging In.'s outstanding common and preferred shares for ... offer substantial value propositions to the dental industry, which this acquisition will allow ...
(Date:8/9/2020)... , ... August 09, 2020 , ... ... on sustainable results, today announced that Lydia C. Alexander, MD, has joined the ... medicine specialist, Dr. Alexander will play a vital role in expanding Enara Health’s ...
(Date:8/7/2020)... ... 07, 2020 , ... Glewed TV, a leading video-on-demand (VOD) ... content, today announced a partnership with award-winning director Charles Mattocks to air Eight ... The first reality TV series of its kind, Eight Days first aired on ...
Breaking Medicine Technology: